A trial of datopotamab deruxtecan with or without durvalumab for triple negative breast cancer (TROPION-Breast03)

This trial is comparing datopotamab deruxtecan with and without durvalumab to chemotherapy and immunotherapy. It is for triple negative breast cancer. It is open to people with stage 1-3 triple negative breast cancer that:

• have had treatment to their cancer before surgery (neoadjuvant treatment) and

• the cancer has not completely gone at the time of surgery (residual invasive disease)